European Union - English - EMA (European Medicines Agency)

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - vaccines - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age.the use of qdenga should be in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vaccines - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4.2, 4.4 and 4.8).the use of dengvaxia should be in accordance with official recommendations.

Philippines - English - FDA (Food And Drug Administration)

zuellig pharma corporation - dengue tetravalent vaccine (live, attenuated) (see formulation on reverse side) - powder for suspension for injection sc

Philippines - English - FDA (Food And Drug Administration)

zuellig pharma corporation - dengue tetravalent vaccine (live, attenuated) (see formulation on reverse side) - powder for suspension for injection sc

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - chimeric yellow fever dengue virus serotype 1, quantity: 6 ccid50; chimeric yellow fever dengue virus serotype 2, quantity: 6 ccid50; chimeric yellow fever dengue virus serotype 3, quantity: 6 ccid50; chimeric yellow fever dengue virus serotype 4, quantity: 6 ccid50 - suspension, powder for - excipient ingredients: cystine; tyrosine; arginine hydrochloride; histidine; isoleucine; leucine; lysine hydrochloride; methionine; phenylalanine; threonine; tryptophan; alanine; asparagine; aspartic acid; glutamic acid; proline; serine; glycine; sucrose; trehalose dihydrate; sorbitol; trometamol; urea; valine - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 9 through 45 years of age living in endemic areas. use should be in accordance with official guidelines (see dosage and administration).

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - dengue-yellow fever chimeric virus serotype 1 live (attenuated) antigen (unii: 75kb2hpx5h) (dengue-yellow fever chimeric virus serotype 1 live (attenuated) antigen - unii:75kb2hpx5h), dengue-yellow fever chimeric virus serotype 2 live (attenuated) antigen (unii: fh5svg7glc) (dengue-yellow fever chimeric virus serotype 2 live (attenuated) antigen - unii:fh5svg7glc), dengue-yellow fever chimeric virus serotype 3 live (attenuated) antigen (unii: rht2q37fyg) (dengue-yellow fever chimeric virus serotype 3 liv - dengvaxia® (dengue tetravalent vaccine, live) is a vaccine indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3, and 4. dengvaxia is approved for use in individuals 6 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas. limitations of use - dengvaxia is not approved for use in individuals younger than 6 years of age. these individuals, regardless of previous infection by dengue virus, are at increased risk of severe and hospitalized dengue disease following vaccination with dengvaxia and subsequent infection with any dengue virus serotype. [see warnings and precautions (5.1).] - dengvaxia is not approved for use in individuals not previously infected by any dengue virus serotype or for whom this information is unknown. those not previously infected are at increased risk for severe dengue disease when vaccinated and subsequently infected with dengue virus. [see warnings and precautions (5.1).] previous dengue infection c

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - live attenuated yellow fever virus strain 17 d - injection - live attenuated yellow fever virus strain 17 d not less than 1000 iu

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - yellow fever virus, quantity: 1000 pfu e.1000 mouse ld50 - injection, powder for - excipient ingredients: calcium chloride dihydrate; magnesium sulfate heptahydrate; histidine hydrochloride; sodium chloride; dibasic sodium phosphate dihydrate; alanine; sorbitol; potassium chloride; lactose monohydrate; monobasic potassium phosphate; sodium hydroxide - prevention of yellow fever. vaccination is recommended for:,? every person over 9 months of age living or travelling through an endemic area. ? non-vaccinated persons moving from an endemic to a potentially receptive non-endemic area. ? laboratory workers handling potentially infectious materials. in order to be officially recognised, the yellow fever vaccination must be administered in an approved vaccination centre and registered on an international certificate. the validity period of the certificate is established according to international health regulations recommendations and starts 10 days after primary vaccination and immediately after re-vaccination.

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - cyd dengue virus serotype 1; cyd dengue virus serotype 2; cyd dengue virus serotype 3; cyd dengue virus serotype 4 - injection, powder, for suspension - cyd dengue virus serotype 1 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 2 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 3 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 4 4.5 - 6.0 log10 ccid50/dose

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - cyd dengue virus serotype 1; cyd dengue virus serotype 2; cyd dengue virus serotype 3; cyd dengue virus serotype 4 - injection, powder, for suspension - cyd dengue virus serotype 1 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 2 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 3 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 4 4.5 - 6.0 log10 ccid50/dose